Figure 1.
Analysis of miR-195 expression in glioma cell lines and tissues. A
, Real-time PCR analysis of miR-195 expression in normal human astrocytes NHA and glioma cell lines, including A172, LN340, U118MG, LN464, SNB19, LN18, T98G, U251MG and LN235. The average miR-195 expression was normalized to U6 expression. B, The expression of miR-195 was examined in paired primary glioma tissues (T) and glioma adjacent nontumor tissues (ANT) from eight individual patients. The average miR-195 expression was normalized to U6 expression. Each bar represents the mean of three independent experiments. * P<0.05.
Figure 2.
Upregulation of miR-195 suppresses the proliferation of glioma cells. A
, MTT assays revealed that upregulation of miR-195 reduced cell growth of LN18 and T98G glioma cell lines, compared to negative control (NC)-transfected cells. B, Upregulation of miR-195 reduced glioma cell tumorigenicity as determined by anchorage-independent growth assay. Representative micrographs (left) and quantification of colonies that were larger than 0.1 mm (right) were scored. C, Representative micrographs (left) and quantification of BrdU incorporating-cells after transfection with negative control (NC) or miR-195. D, Flow cytometric analysis of indicated glioma cells after transfection with Negative control (NC) or miR-195. Each bar represents the mean of three independent experiments. * P<0.05.
Figure 3.
Inhibition of miR-195 promotes glioma cell proliferation. A
, MTT assays revealed that inhibition of miR-195 promoted cell growth of glioma cell lines of LN18 and T98G. B, Inhibition of miR-195 promoted the anchorage-independent growth of glioma cells. Representative micrographs (left) and quantification of colonies that were larger than 0.1 mm (right) were scored. C, Representative micrographs (left) and quantification of BrdU incorporating-cells after transfection with NC or miR-195 inhibitor. D, Flow cytometric analysis of indicated glioma cells after transfection with NC or miR-195 inhibitor. Each bar represents the mean of three independent experiments. * P<0.05.
Figure 4.
miR-195 downregulates cyclin D1 and cyclin E1 by directly targeting their 3
′-UTRs. A, Predicted miR-195 target sequence in the 3′-UTR of cyclin D1 and cyclin E1 (cyclin D1 3′-UTR and cyclin E1 3′-UTR) and illustration of the three altered nucleotides in miR-195-mut. B, Western blotting analysis of expression of phosphorylated Rb (p-Rb), total Rb, PCNA, cyclin D1, cyclin E1, CDK2 and p21 in indicated cells. α-Tubulin served as the loading control. C, Western blotting analysis of GFP expression in indicated cells. D, Luciferase assay of indicated cells transfected with the pGL3-cyclin D1-3′UTR reporter (left) or the pGL3-cyclin E1-3′UTR reporter (right) with increasing amounts (10, 50 nM) of miR-195 mimic, or miR-195 inhibitor, or miR-195 mutant. Each bar represents the mean ± SD of three independent experiments. * P<0.05.
Figure 5.
miR-195 inhibits glioma proliferation in vivo. A.
Real-time PCR analysis of miR-195 expression in LN18-Vector and LN18-miR-195 stable cell lines. B. Western blotting analysis of Cyclin D1 and Cyclin E1 expression in vector- or miR-195-transduced cells. C. Representative micrographs (left panel) and quantification (right panel) of colonies determined by anchorage-independent growth assays. D–F. Xenograft model in nude mice. Indicated cells were injected into the dorsal flank of the mice. (D), Images of the tumors from all mice. (E), Tumor volumes were measured on the indicated days. (F), Mean tumor weights.
Figure 6.
miR-195 expression inversely correlates with Cyclin D1 and Cyclin E1 expression in glioma tissues.
Analysis (left) and correlation (right) between miR-195 expression and Cyclin D1 and Cyclin E1 expression levels in 10 freshly collected human glioma samples. Each bar represents the mean ± SD of three independent experiments.